| Literature DB >> 32004316 |
Ashley Sharp1, Alexandre Blake2, Jérôme Backx3, Isabella Panunzi3, Robert Barrais4, Fabienne Nackers2, Francisco Luquero2, Yves Gaston Deslouches4, Sandra Cohuet2.
Abstract
Oral cholera vaccine (OCV) has increasingly been used as an outbreak control measure, but vaccine shortages limit its application. A two-dose OCV campaign targeting residents aged over 1 year was launched in three rural Communes of Southern Haiti during an outbreak following Hurricane Matthew in October 2016. Door-to-door and fixed-site strategies were employed and mobile teams delivered vaccines to hard-to-reach communities. This was the first campaign to use the recently pre-qualified OCV, Euvichol. The study objective was to estimate post-campaign vaccination coverage in order to evaluate the campaign and guide future outbreak control strategies. We conducted a cluster survey with sampling based on random GPS points. We identified clusters of five households and included all members eligible for vaccination. Local residents collected data through face-to-face interviews. Coverage was estimated, accounting for the clustered sampling, and 95% confidence intervals calculated. 435 clusters, 2,100 households and 9,086 people were included (99% response rate). Across the three communes respectively, coverage by recall was: 80.7% (95% CI:76.8-84.1), 82.6% (78.1-86.4), and 82.3% (79.0-85.2) for two doses and 94.2% (90.8-96.4), 91.8% (87-94.9), and 93.8% (90.8-95.9) for at least one dose. Coverage varied by less than 9% across age groups and was similar among males and females. Participants obtained vaccines from door-to-door vaccinators (53%) and fixed sites (47%). Most participants heard about the campaign through community 'criers' (58%). Despite hard-to-reach communities, high coverage was achieved in all areas through combining different vaccine delivery strategies and extensive community mobilisation. Emergency OCV campaigns are a viable option for outbreak control and where possible multiple strategies should be used in combination. Euvichol will help alleviate the OCV shortage but effectiveness studies in outbreaks should be done.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32004316 PMCID: PMC7015427 DOI: 10.1371/journal.pntd.0007967
Source DB: PubMed Journal: PLoS Negl Trop Dis ISSN: 1935-2727
Fig 1Cholera vaccination coverage by Commune, age group and assessment method, South Department, Haiti, 2017.
Fig 2Self-reported cholera vaccination coverage by Commune, age and gender, South Department, Haiti, 2017.
Fig 3Interpolation of the spatial variation in self-reported cholera vaccination coverage, with standard error and position of GPS points, South Department, Haiti, 2017.
Maps produced using R using GADM shapefiles for the boundaries.
Source of information about the vaccination campaign by dose and Commune, South Department, Haiti, 2017.
| Dose 1 | Dose 2 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chardonnières | Côteaux | Port-à-Piment | Chardonnières | Côteaux | Port-à-Piment | |||||||
| % | 95% CI | % | 95% CI | % | 95% CI | % | 95% CI | % | 95% CI | % | 95% CI | |
| I was not aware that there was a vaccination campaign | 0.3 | 0.1–0.6 | 0.2 | 0.1–0.7 | 0.3 | 0.1–0.6 | 0.3 | 0.1–0.6 | 0.1 | 0.0–0.4 | 0.2 | 0.0–0.9 |
| Television / Radio | 0.1 | 0.0–0.3 | 0.1 | 0.0–0.3 | 1.9 | 1.2–3.1 | 0.1 | 0.0–0.3 | 0.1 | 0.0–0.3 | 2.1 | 1.3–3.3 |
| Newspaper | 0.1 | 0.0–0.4 | 0.1 | 0.0–0.4 | 0.6 | 0.3–0.9 | 0.7 | 0.4–1.2 | 0.5 | 0.2–1.1 | 1.3 | 0.8–2.2 |
| Church / mosque | 3.8 | 2.8–5.0 | 1.4 | 0.9–2.2 | 7.5 | 5.8–9.5 | 3.7 | 2.0.7–5 | 1.1 | 0.6–1.8 | 7.7 | 6.0–9.7 |
| By friends / neighbours | 5.3 | 4.0–7.0 | 3.0 | 2.0–4.5 | 6.7 | 5.1–8.6 | 5.2 | 3.9–6.9 | 3.1 | 2.0–4.6 | 6.6 | 5.1–8.5 |
| Village leader / neighbourhood leader / political leader | 0.6 | 0.3–1.2 | 1.2 | 0.7–2.1 | 1.0 | 0.5–1.8 | 0.6 | 0.3–1.1 | 1.2 | 0.0.7–2 | 0.9 | 0.5–1.7 |
| Vaccinators / nursing staff | 14.9 | 12.4–17.9 | 11.5 | 9.4–14.1 | 8.7 | 6.9–10.9 | 15.0 | 12.4–17.9 | 11.7 | 9.5–14.4 | 8.5 | 6.7–10.7 |
| Family members | 7.8 | 6.4–9.4 | 6.3 | 5.2–7.6 | 6.6 | 5.4–8.1 | 7.7 | 6.3–9.2 | 6.3 | 5.2–7.5 | 6.5 | 5.3–8.0 |
| When pre-marking homes | 0.3 | 0.1–0.8 | 0.2 | 0.0–0.6 | 0.2 | 0.1–0.5 | 0.2 | 0.1–0.7 | 0.1 | 0.0–0.7 | 0.2 | 0.1–0.5 |
| Banners. flyers. or posters | 4.9 | 3.3–7.2 | 4.2 | 2.8–6.2 | 3.8 | 2.6–5.7 | 4.8 | 3.2–7.1 | 4.1 | 2.8–6.1 | 3.8 | 2.5–5.6 |
| Schools / markets | 6.0 | 4.8–7.6 | 2.9 | 2.2–3.7 | 5.2 | 4.2–6.4 | 7.4 | 6.0–9.0 | 3.2 | 2.5–4.1 | 5.9 | 4.8–7.1 |
| Criers | 53.5 | 49.8–57 | 67.5 | 64.2–70.7 | 55.2 | 52.0–58.4 | 52.6 | 49.0–56.2 | 67.3 | 64–70.4 | 54.2 | 51–57.4 |
| Community meetings | 0.4 | 0.2–0.7 | 0.2 | 0.1–0.4 | 0.2 | 0.0–1.3 | 0.2 | 0.1–0.4 | 0.2 | 0.0–0.8 | 0.3 | 0.1–1.2 |
| An NGO | 0 | 0.0–0.0 | 0 | 0.0–0.0 | 0.3 | 0.1–0.6 | 0 | 0.0–0.0 | 0 | 0.0–0.0 | 0.2 | 0.1–0.5 |
| Other | 2.1 | 1.3–3.6 | 1.2 | 0.8–1.9 | 1.8 | 1.2–2.8 | 1.8 | 1.0–3.2 | 1.1 | 0.7–1.8 | 1.6 | 1.0–2.4 |
Adverse events reported by dose and Commune, South Department, Haiti, 2017.
| Dose 1 | Dose 2 | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chardonnières | Côteaux | Port-à-Piment | Chardonnières | Côteaux | Port-à-Piment | |||||||||
| % | 95% CI | % | 95% CI | % | 95% CI | % | 95% CI | % | 95% CI | % | 95% CI | |||
| Rate of adverse events | 4.6 | 3.8–5.7 | 2.9 | 2.3–3.7 | 5.7 | 4.6–6.9 | 4.9 | 4–6.1 | 3.1 | 2.4–3.9 | 6.8 | 5.6–8.3 | ||
| Type of adverse event | Nothing | 0.8 | 0.1–5.3 | 1.1 | 0.2–8 | 0.7 | 0.1–4.6 | 1.4 | 0.3–5.6 | 3.3 | 1–9.9 | 0.5 | 0.1–3.8 | |
| Fever | 2.3 | 0.5–9.4 | 3.4 | 1.1–10.5 | 0.7 | 0.1–4.7 | 2.8 | 0.8–9.1 | 3.3 | 1–10 | 2.2 | 0.8–5.6 | ||
| Diarrhoea | 9.8 | 4.8–19.1 | 12.6 | 6.8–22.4 | 13.2 | 8.1–20.7 | 7.1 | 3.8–12.8 | 11.0 | 5.1–22.2 | 12.9 | 7.4–21.5 | ||
| Abdominal pain | 9.1 | 5–16.1 | 2.3 | 0.6–9 | 9.9 | 5.7–16.4 | 7.8 | 4.2–14.2 | 4.4 | 1.6–11.3 | 8.1 | 4.8–13.3 | ||
| Nausea | 7.6 | 3.9–14.1 | 5.7 | 2.4–13 | 11.2 | 6.7–18 | 5.0 | 2.2–11 | 3.3 | 1–9.9 | 11.3 | 7.2–17.2 | ||
| Vomiting | 4.5 | 2–9.9 | 4.6 | 1.4–14.4 | 5.3 | 2.4–11 | 6.4 | 3.3–11.9 | 3.3 | 1–10 | 5.4 | 2.5–11.2 | ||
| Headache | 26.5 | 19.1–35.5 | 26.4 | 17.7–37.5 | 17.8 | 11.5–26.5 | 23.4 | 16.3–32.4 | 22.0 | 14.7–31.6 | 22.0 | 16–29.5 | ||
| Weakness / fatigue | 26.5 | 19.4–35.1 | 32.2 | 23.1–42.8 | 30.9 | 23.4–39.7 | 36.2 | 28–45.3 | 39.6 | 29.8–50.2 | 25.8 | 19.6–33.1 | ||
| Other | 12.9 | 7.8–20.5 | 11.5 | 5.6–22 | 10.5 | 5.7–18.7 | 9.9 | 5.8–16.6 | 9.9 | 4.8–19.4 | 11.8 | 7.3–18.6 | ||
| Consultation in a health centre following adverse event | 13.6 | 8–22.3 | 16.1 | 9.2–26.7 | 5.9 | 3.1–11.1 | 12.8 | 7.7–20.5 | 5.5 | 2.3–12.5 | 4.8 | 2.5–9.2 | ||